GLP-1s Are Being Linked to Fewer Serious Infections, Including TB

Recent studies have found that GLP-1 medications like semaglutide and tirzepatide are linked to reduced risks of serious infections, including tuberculosis and hospital-requiring infections, particularly among people with type 2 diabetes. While the exact mechanisms remain unclear, researchers suggest these drugs may offer protective benefits beyond their established metabolic effects, though more research is needed to confirm these connections.